# The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients

Study · id `cardio:ct-nct07739160` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07739160](<https://clinicaltrials.gov/study/NCT07739160>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07739160

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 340 participants.

## Technical summary

Registry record NCT07739160. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-29 (actual); primary completion 2027-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 340 participants (planned count; ClinicalTrials.gov record NCT07739160, source copy `cardio:ctgov-nct07739160-2026-11-05`, retrieved 2026-11-18)
- Started: 2026-09-29 (actual) (ClinicalTrials.gov record NCT07739160, source copy `cardio:ctgov-nct07739160-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2027-04 (anticipated) (ClinicalTrials.gov record NCT07739160, source copy `cardio:ctgov-nct07739160-2026-11-05`, retrieved 2026-11-18)
- Completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT07739160, source copy `cardio:ctgov-nct07739160-2026-11-05`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07739160, source copy `cardio:ctgov-nct07739160-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07739160-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients
- Condition: Acute Ischemic Stroke
- Intervention (Drug): HRS-4029
- Intervention (Drug): Placebo
- Lead sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd (`cardio:org-beijing-suncadia-pharmaceuticals-co-ltd`)

## Provenance

Content hash: 67fd2a05e28497b68e8601e62aae467420fa8befd5450c0edcec16e0eb47d89a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
